Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986 · cited 3×
“Amyloidassociated pathologies include dystrophic synaptic boutons, hyperphosphorylated tau-positive neuritic structures and robust gliosis and microglia activation that increase 3-fold from 1 to 8 months of age (Radde et al., 2006).”
BackgroundInfluentialSelf-citationBrain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Hamilton, A., & Hölscher, C. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832fbf14 · Cited by 227
Self-citationBondolfi, L., Calhoun, M., Ermini, F., Kuhn, H. G., Wiederhold, K.-H., Walker, L., Staufenbiel, M., & Jucker, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-02-00515.2002 · Cited by 213
Using paired-pulse facilitation to probe the mechanisms for long-term potentiation (LTP)
Schulz, P., Cook, E., & Johnston, D. (1995) · Journal of Physiology-Paris · doi:10.1016/0928-4257(96)80546-8 · Cited by 103
Green, B. D., Lavery, K. S., Irwin, N., O’Harte, F. P. M., Harriott, P., Greer, B., Bailey, C. J., & Flatt, P. R. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097824 · Cited by 49
Research works printed but not linked: 52
- Abbas, 2009, Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease, Behav. Brain Res, 205, 265, 10.1016/j.bbr.2009.06.035 · DOI · Paper page
- Aubert-Pouessel, 2004, In vitro study of GDNF release from biodegradable PLGA microspheres, J. Control. Release, 95, 463, 10.1016/j.jconrel.2003.12.012 · DOI
- Azzouz, 2004, VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model, Nature, 429, 413, 10.1038/nature02544 · DOI · Paper page
- Biessels, 2006, Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus, J. Neurol. Neurosurg. Psychiatry, 77, 304, 10.1136/jnnp.2005.069583 · DOI · Paper page
- Biswas, 2008, Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction, Neurochem. Res, 33, 1845, 10.1007/s11064-008-9646-4 · DOI
- Blurton-Jones, 2009, Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease, Proc. Natl. Acad. Sci. U. S. A., 106, 13594, 10.1073/pnas.0901402106 · DOI · Paper page
- Bradbury, 2005, Hope for AD with NGF gene-therapy trial, Lancet Neurol, 4, 335, 10.1016/S1474-4422(05)70086-7 · DOI
- Carro, 2004, Insulin-like growth factor I and Alzheimer's disease: therapeutic prospects?, In Expert Rev. Neurother, 4, 79, 10.1586/14737175.4.1.79 · DOI · Paper page
- Carro, 2004, The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease, Eur. J. Pharmacol, 490, 127, 10.1016/j.ejphar.2004.02.050 · DOI · Paper page
- Chen, 1996, Synaptic release rather than failure in the conditioning pulse results in paired-pulse facilitation during minimal synaptic stimulation in the rat hippocampal CA1 neurones, Neurosci. Lett, 218, 204, 10.1016/S0304-3940(96)13149-9 · DOI
- Clarris, 1994, Secretion of nerve growth factor from septum stimulates neurite outgrowth and release of the amyloid protein precursor of Alzheimer's disease from hippocampal explants, J. Neurosci. Res, 38, 248, 10.1002/jnr.490380303 · DOI · Paper page
- Covaceuszach, 2009, Development of a non invasive NGF-based therapy for Alzheimer's disease, Curr. Alzheimer Res, 6, 158, 10.2174/156720509787602870 · DOI · Paper page
- Cummings, 2002, Optimization of techniques for the maximal detection and quantification of Alzheimer's-related neuropathology with digital imaging, Neurobiol. Aging, 23, 161, 10.1016/S0197-4580(01)00316-5 · DOI
- Dickson, 1997, The pathogenesis of senile plaques, J. Neuropathol. Exp. Neurol, 56, 321, 10.1097/00005072-199704000-00001 · DOI · Paper page
- Gault, 2008, GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid, Eur. J. Pharmacol, 587, 112, 10.1016/j.ejphar.2008.03.025 · DOI
- Gault, 2003, Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes, Biochem. Biophys. Res. Commun, 308, 207, 10.1016/S0006-291X(03)01361-5 · DOI
- Gault, 2008, GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid, Eur. J. Pharmacol, 587, 112, 10.1016/j.ejphar.2008.03.025 · DOI
- Gengler, 2007, Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25–35) are dependent on stimulation-protocol and genetic background, Exp. Brain Res, 179, 621, 10.1007/s00221-006-0819-6 · DOI
- Gengler, 2010, Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice, PLoS ONE, 10.1371/journal.pone.0009764 · DOI · Paper page
- Gilman, 2003, Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons, J. Neurochem, 87, 1137, 10.1046/j.1471-4159.2003.02073.x · DOI · Paper page
- Green, 2007, Incretin hormone mimetics and analogues in diabetes therapeutics, Best Pract. Res. Clin. Endocrinol. Metab, 21, 497, 10.1016/j.beem.2007.09.003 · DOI
- Green, 2004, Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid, Arch. Biochem. Biophys, 428, 136, 10.1016/j.abb.2004.05.005 · DOI
- Green, 2005, A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, Diabetes Obes. Metab, 7, 595, 10.1111/j.1463-1326.2004.00455.x · DOI
- Gregory-Evans, 2009, Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration, Mol. Vis, 15, 962
- Heese, 2006, Nerve growth factor, neural stem cells and Alzheimer's disease, Neuro Signals, 15, 1, 10.1159/000094383 · DOI · Paper page
- Hoyer, 2004, Glucose metabolism and insulin receptor signal transduction in Alzheimer disease, Eur. J. Pharmacol, 490, 115, 10.1016/j.ejphar.2004.02.049 · DOI · Paper page
- Hwang, 2009, Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice, Gene Ther, 16, 1234, 10.1038/gt.2009.80 · DOI
- Hölscher, 2007, Soluble beta-amyloid[25–35] reversibly impairs hippocampal synaptic plasticity and spatial learning, Eur. J. Pharmacol, 561, 85, 10.1016/j.ejphar.2007.01.040 · DOI
- Hölscher, 2008, New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's Disease?, Neurobiol. Aging
- Kastin, 2003, Entry of exendin-4 into brain is rapid but may be limited at high doses, Int. J. Obes. Relat. Metab. Disord, 27, 313, 10.1038/sj.ijo.0802206 · DOI · Paper page
- Kordower, 1997, Cellular delivery of NGF does not alter the expression of beta-amyloid immunoreactivity in young or aged nonhuman primates, Exp. Neurol, 145, 586, 10.1006/exnr.1997.6492 · DOI
- Lee, 2007, Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model, PLoS ONE, 2, e156, 10.1371/journal.pone.0000156 · DOI · Paper page
- Leech, 1997, Insulinotropic glucagon-like peptide-1-mediated activation of non-selective cation currents in insulinoma cells is mimicked by maitotoxin, J. Biol. Chem, 272, 17987, 10.1074/jbc.272.29.17987 · DOI · Paper page
- Li, 2007, Common pathological processes in Alzheimer Disease and Type 2 Diabetes: a review, Brain Res. Rev, 56, 384, 10.1016/j.brainresrev.2007.09.001 · DOI · Paper page
- Luchsinger, 2004, Hyperinsulinemia and risk of Alzheimer disease, Neurology, 63, 1187, 10.1212/01.WNL.0000140292.04932.87 · DOI · Paper page
- Nagano, 2005, Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis, Neurol Rev, 27, 768
- Okamoto, 1994, Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction, J. Biol. Chem, 269, 1231, 10.1016/S0021-9258(17)42247-2 · DOI · Paper page
- Paresce, 1997, Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells, J. Biol. Chem, 14, 29390, 10.1074/jbc.272.46.29390 · DOI · Paper page
- Perry, 2003, Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron, J. Neurosci. Res, 72, 603, 10.1002/jnr.10611 · DOI · Paper page
- Perry, 2004, A new Alzheimer's disease interventive strategy: GLP-1, Curr. Drug Targets, 5, 565, 10.2174/1389450043345245 · DOI · Paper page
- Poon, 2009, beta-Amyloid impairs axonal BDNF retrograde trafficking, Neurobiol. Aging
- Ristow, 2004, Neurodegenerative disorders associated with diabetes mellitus, J. Mol. Med, 82, 510, 10.1007/s00109-004-0552-1 · DOI · Paper page
- Sarkar, 2003, Glucagon like peptide-1 (7–36) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus, Brain Res, 985, 163, 10.1016/S0006-8993(03)03117-2 · DOI
- Schulte-Herbruggen, 2007, Neurotrophic factors − a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases?, Curr. Med. Chem, 14, 2318, 10.2174/092986707781745578 · DOI · Paper page
- Shi, 2005, Differential effects of aging and insulin-like growth factor-1 on synapses in CA1 of rat hippocampus, Cereb. Cortex, 15, 571, 10.1093/cercor/bhh158 · DOI · Paper page
- Sorenson, 2008, Subcutaneous IGF-1 is not beneficial in 2-year ALS trial, Neurology, 71, 1770, 10.1212/01.wnl.0000335970.78664.36 · DOI · Paper page
- Suzuki, 1997, Localization of the ATP-sensitive K+ channel subunit Kir62 in mouse pancreas, Diabetes, 46, 1440, 10.2337/diab.46.9.1440 · DOI · Paper page
- Terzi, 2008, Adeno-associated virus-mediated gene delivery approaches for the treatment of CNS disorders, Biotechnol. J, 3, 1555, 10.1002/biot.200800284 · DOI · Paper page
- Tsai, 2008, Seizures induced by GABAB-receptor blockade in early-life induced long-term GABA(B) receptor hypofunction and kindling facilitation, Epilepsy Res, 79, 187, 10.1016/j.eplepsyres.2008.02.001 · DOI
- Wheeler, 1994, Roles of N-type and Q-type Ca2+ channels in supporting hippocampal synaptic transmission, Science, 264, 107, 10.1126/science.7832825 · DOI · Paper page
- Wilcock, 2006, Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain, Nat. Protoc, 1, 1591, 10.1038/nprot.2006.277 · DOI · Paper page
- Winder, 1993, Activation of metabotropic glutamate receptors increases cAMP accumulation in hippocampus by potentiating responses to endogenous adenosine, J. Neurosci, 13, 38, 10.1523/JNEUROSCI.13-01-00038.1993 · DOI · Paper page
Cited by
Bomfim, T. R., Forny-Germano, L., Sathler, L. B., Brito-Moreira, J., Houzel, J.-C., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 832
Self-citationMcClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Self-citationChen, Z., & Zhong, C. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.004 · Cited by 673
Kapogiannis, D., & Mattson, M. P. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70277-5 · Cited by 594
Hippocampal insulin resistance and cognitive dysfunction
Biessels, G. J., & Reagan, L. P. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4019 · Cited by 537
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504
“The protease resistant and long-lasting GLP-1 analogue Val(8) GLP-1 enhanced synaptic plasticity in acute and chronic application and preserved synaptic functionality in the brains of a mouse model of AD [14,15].”
BackgroundResultSelf-citationGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
“1473, 204–213 26 Gengler, S. et al. (2012) Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice.”
BackgroundMcClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.005 · Cited by 361
Self-citationInsulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P.-O., Bezard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 309
Drug repositioning for Alzheimer's disease
Corbett, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 301
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
Hölscher, C. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0221 · Cited by 288
Self-citationSalcedo, I., Tweedie, D., Li, Y., & Greig, N. H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01971.x · Cited by 259
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Self-citationHamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210
Self-citationDrug repositioning and repurposing for Alzheimer disease
Ballard, C., Aarsland, D., Cummings, J., O’Brien, J., Mills, R., Molinuevo, J. L., Fladby, T., Williams, G., Doherty, P., Corbett, A., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0397-4 · Cited by 201
Salameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188
“Facilitating synaptic plasticity and cognitive function [38-41, 50, 147, 148, 154, 156-160, 162, 174-183].”
BackgroundMcClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.015 · Cited by 170
Self-citationThe mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Du, H., Meng, X., Yao, Y., & Xu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1033479 · Cited by 125
Zhang, B., Yan, W., Zhu, Y., Yang, W., Le, W., Chen, B., Zhu, R., & Cheng, L. (2018) · Advanced Materials · doi:10.1002/adma.201705694 · Cited by 113
GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
“In the same mouse model, the GLP-1 receptor analog Val8-GLP-1 was shown to prevent or delay agerelated synaptic neurodegenerative processes (77).”
BackgroundMcIntyre, R. S., Powell, A. M., Kaidanovich-Beilin, O., Soczynska, J. K., Alsuwaidan, M., Woldeyohannes, H. O., Kim, A. S., & Gallaugher, L. A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.09.021 · Cited by 110
Cai, H.-Y., Yang, J.-T., Wang, Z.-J., Zhang, J., Yang, W., Wu, M.-N., & Qi, J.-S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.114 · Cited by 108
Wang, X. H., Li, L., Hölscher, C., Pan, Y. F., Chen, X. R., & Qi, J. S. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.028 · Cited by 99
Self-citationCalsolaro, V., & Edison, P. (2015) · CNS Drugs · doi:10.1007/s40263-015-0301-8 · Cited by 93
The Role of GLP-1 in Neuronal Activity and Neurodegeneration
Hölscher, C. (2010) · Vitamins & Hormones · doi:10.1016/b978-0-12-381517-0.00013-8 · Cited by 74
Self-citationBao, Y., Jiang, L., Chen, H., Zou, J., Liu, Z., & Shi, Y. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430199 · Cited by 60
Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Mayfield, K., Siskind, D., Winckel, K., Russell, A. W., Kisely, S., Smith, G., & Hollingworth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625496 · Cited by 49
Rebosio, C., Balbi, M., Passalacqua, M., Ricciarelli, R., & Fedele, E. (2018) · BioFactors · doi:10.1002/biof.1406 · Cited by 46
Metadata
- Authors
- Gengler, S., McClean, P. L., McCurtin, R., Gault, V. A., & Hölscher, C.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 33
- Issue
- 2
- Pages
- 265-276
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2065789765
- Cited by
- 160
- References
- 10
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.